中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2008年
11期
938-941
,共4页
谢宇%朱亭%钟毅%刘娟%俞静%查娟明%狄文娟%丁国宪
謝宇%硃亭%鐘毅%劉娟%俞靜%查娟明%狄文娟%丁國憲
사우%주정%종의%류연%유정%사연명%적문연%정국헌
胰岛素抗药性%11β-羟化类固醇脱氢酶1%BVT.2733
胰島素抗藥性%11β-羥化類固醇脫氫酶1%BVT.2733
이도소항약성%11β-간화류고순탈경매1%BVT.2733
Insulin resistance%11β-hydroxysteroid dehydrogenase 1%BVT. 2733
目的 观察BVT.2733和吡格列酮(PGZ)对肥胖小鼠干预结果的异同,探讨BVT.2733在改善胰岛素抵抗中的作用机制.方法 构建高脂饮食诱导的肥胖小鼠模型,分为正常对照组、肥胖对照组、BVT.2733治疗组、PGZ治疗组,对照组给予安慰剂,治疗组分别给予BVT.2733、PGZ灌胃2周,放免法检测小鼠空腹胰岛素水平,生化法检测血糖,ELISA法检测血清脂联素含量,实时定量PCR检测脂肪组织脂联素和瘦素的mRNA表达.观察4组小鼠在胰岛素抵抗方面的差异.结果 与正常对照组相比,肥胖对照组小鼠脂肪细胞明显增大,体重增加,空腹血糖、血清胰岛素水平升高(P<0.05).与肥胖对照组比较,BVT.2733、PGZ治疗组鼠脂肪细胞体积减小,空腹血清胰岛素明显下降(P<0.01);PGZ组血清脂联素含量升高、脂肪组织脂联素和瘦素表达明显上调(P<0.05).BVT.2733治疗组小鼠体重明显减轻,而血清脂联素含量、脂肪组织脂联素和瘦素表达变化无统计学意义.结论 BVT.2733能够显著减轻体重,改善胰岛素抵抗,但其不能影响脂肪细胞的分泌功能.
目的 觀察BVT.2733和吡格列酮(PGZ)對肥胖小鼠榦預結果的異同,探討BVT.2733在改善胰島素牴抗中的作用機製.方法 構建高脂飲食誘導的肥胖小鼠模型,分為正常對照組、肥胖對照組、BVT.2733治療組、PGZ治療組,對照組給予安慰劑,治療組分彆給予BVT.2733、PGZ灌胃2週,放免法檢測小鼠空腹胰島素水平,生化法檢測血糖,ELISA法檢測血清脂聯素含量,實時定量PCR檢測脂肪組織脂聯素和瘦素的mRNA錶達.觀察4組小鼠在胰島素牴抗方麵的差異.結果 與正常對照組相比,肥胖對照組小鼠脂肪細胞明顯增大,體重增加,空腹血糖、血清胰島素水平升高(P<0.05).與肥胖對照組比較,BVT.2733、PGZ治療組鼠脂肪細胞體積減小,空腹血清胰島素明顯下降(P<0.01);PGZ組血清脂聯素含量升高、脂肪組織脂聯素和瘦素錶達明顯上調(P<0.05).BVT.2733治療組小鼠體重明顯減輕,而血清脂聯素含量、脂肪組織脂聯素和瘦素錶達變化無統計學意義.結論 BVT.2733能夠顯著減輕體重,改善胰島素牴抗,但其不能影響脂肪細胞的分泌功能.
목적 관찰BVT.2733화필격렬동(PGZ)대비반소서간예결과적이동,탐토BVT.2733재개선이도소저항중적작용궤제.방법 구건고지음식유도적비반소서모형,분위정상대조조、비반대조조、BVT.2733치료조、PGZ치료조,대조조급여안위제,치료조분별급여BVT.2733、PGZ관위2주,방면법검측소서공복이도소수평,생화법검측혈당,ELISA법검측혈청지련소함량,실시정량PCR검측지방조직지련소화수소적mRNA표체.관찰4조소서재이도소저항방면적차이.결과 여정상대조조상비,비반대조조소서지방세포명현증대,체중증가,공복혈당、혈청이도소수평승고(P<0.05).여비반대조조비교,BVT.2733、PGZ치료조서지방세포체적감소,공복혈청이도소명현하강(P<0.01);PGZ조혈청지련소함량승고、지방조직지련소화수소표체명현상조(P<0.05).BVT.2733치료조소서체중명현감경,이혈청지련소함량、지방조직지련소화수소표체변화무통계학의의.결론 BVT.2733능구현저감경체중,개선이도소저항,단기불능영향지방세포적분비공능.
Objective To investigate the mechanism of BVT. 2733 on insulin resistance, by using diet-induced obese (DIO) mice model. Methods After having been balanced for 3 days, the C57BL/6J mice were randomly divided into a normal diet group and a high-fat diet (HFD) group. After 20 weeks, the obese mice were further randomly divided into an obese control group, a BVT. 2733 group and a pioglltazone (PGZ) group and they were orally administered with placebo, BVT. 2733 and PGZ separately for two weeks.Adiponectin and leptin mRNA expression levels from adipose tissue were analyzed with real-time quantitative PCR. The levels of plasma glucose, serum insulin and adiponectin were measured with biochemical technology, radioimmunoassay and ELISA. Adipocyte sizes were observed with immunohistocbemistry.Results The body weight, plasma glucose and serum insulin levels raised(P<0.05)in the HFD group and the adipocyte sizes were bigger. Serum insulin levels significantly reduced (P<0.05) and adipocyte sizes reduced, while plasma adiponectin level raised (P<0.01)in the two treatment groups as compared with those in obese controls. Both the mRNA expressions of adiponectin and leptin upregulated(P<0.05)in the PGZ group, but their expressions in the BVT. 2733 group did not alter significantly. The body weight of the mice reduced significantly in the BVT. 2733 group. Conclusion BVT. 2733 can reduce body weight significantly and improve insulin resistance, but cannot influence the expression of adipocytokines.